Researchers believe there may be better new crown treatments for severe COVID-19 cases that could lead to complications and deaththane than remdesivir and dexamethasone,media BGR reported. The use of interleukin-6 inhibitors, such as sarilumab and tocilizumab, in patients in need of oxygen and ICU care, may significantly reduce mortality and speed up recovery time, according to a study.
Earlier this year, other researchers first proposed the potentially life-saving treatment, as other researchers have been studying ways to reduce the inflammatory response in patients with COMPLICATIONS OF COVID-19. The conclusions of this study may be useful for future studies, but they are not randomized double-blind placebo-controlled studies.
Doctors at Boston Medical Center (BMC) divided a group of 255 PATIENTs who needed oxygen therapy into two groups, IIB (149) and Stage III (106). Doctors treat patients with interleukal interleukin-6 (IL6ri) inhibitors, such as sarilumab or tocilizumab. These drugs have been used in autoimmune diseases such as rheumatoid arthritis and other inflammatory diseases.
These drugs can respond to a so-called “cytokine storm” that may occur in some PATIENTs with COVID-19, in which case the immune response is not just to attack pathogens and infected cells, but also to healthy tissue.
Doctors first proposed an IL-6 inhibitor-based therapy in April to reduce inflammation in the body, help patients get out of the ventilator and eventually heal. Media BGR reported in mid-June that Redsever maker Gilead Sciences was working on improving COVID-19 therapy, one of which was the combination of Redsiweand and Tocilizumab.
Back in a study published at Boston University in the International Journal of Infectious Diseases, doctors observed that il-6 inhibitors were used earlier in the treatment of 255 patients.
Initially, doctors used the drug in stage III patients or people with high erasing oxygen needs, but later the IIB group joined the drug. BMC researchers observed that patients treated with IL-6 inhibitors had lower mortality rates than those in the intervention and control groups of the Redssewe and Dexametason studies.
“The mortality rate for 105 patients who needed ICU was 22.9 percent, significantly lower than the 45-50 percent mortality rate in other neo-coronavirus studies.” Overall, the use of IL6ri was associated with lower mortality, lower intubation rates, higher likelihood of being discharged alive, and shorter hospital stays,” the researchers wrote.
“The greatest benefits of IL6ri use are seen in patients receiving the drug at an earlier stage, i.e. before critical respiratory decompression, which indicates the importance of timely testing and treatment,” said study researcher Pranay Sinha. “We hope these findings will help guide doctors as we look for solutions that reduce mortality, increase tracheal intubation, reduce hospital stays, and keep more patients alive.”
This is an observational study, which means that the effect of IL-6 inhibitors in COVID-19 management was not objectively measured by a placebo-given control group. Comparisons with Redsee and Dexametason may not be objective either. Still, the study was peer-reviewed, and BMC doctors weren’t the only ones using IL-6 inhibitors as a potential tool to prevent life-threatening cytokine storms in some high-risk patients. The full study is available in this link.